ImmunoVaccine Technologies Inc. (IVT)

ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, and are currently being applied to cervical cancer, with potential for melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases.